Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 3/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25580304 | 1.00 | HSD17B1 (0.36) | HSD17B1HSD17B2HDAC4HDAC2HDAC8 | |
| SCHEMBL25580269 | 0.95 | HSD17B1 (0.42) | HSD17B1HSD17B2HDAC4HDAC2HDAC8 | |
| SCHEMBL25580262 | 0.95 | HSD17B1 (0.42) | HSD17B1HSD17B2HDAC4HDAC2HDAC8 | |
| SCHEMBL25580395 | 0.94 | HSD17B1 (0.39) | HSD17B1HSD17B2HDAC4HDAC2HDAC8 | |
| SCHEMBL25580384 | 0.94 | HSD17B1 (0.39) | HSD17B1HSD17B2HDAC4HDAC2HDAC8 | |
| SCHEMBL25580301 | 0.93 | MCL1 (0.37) | HSD17B1HSD17B2HDAC8 | |
| SCHEMBL25580034 | 0.92 | HSD17B1 (0.34) | HSD17B1HSD17B2HDAC4HDAC2HDAC8 | |
| SCHEMBL25580104 | 0.92 | HSD17B1 (0.34) | HSD17B1HSD17B2HDAC4HDAC2HDAC8 | |
| SCHEMBL25580672 | 0.90 | HSD17B1 (0.37) | HSD17B1HSD17B2HDAC4HDAC2HDAC8 | |
| SCHEMBL25580661 | 0.90 | HSD17B1 (0.37) | HSD17B1HSD17B2HDAC4HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230180597-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| US-20230180597-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230180597-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | ESR1, L1CAM, ESR2 | HSD17B1 3017/4885HSD17B2 2771/4885HDAC4 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.